// App-Quantinova.ai

21 : Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

Researchers

Presenter

  • David Baanstra

Principal Investigators

  • Henry Eriksson

  • Samuel Z. Goldhaber

  • Ajay Kakkar

  • Clive Kearon

  • Sebastian Schellong

  • Jeffrey Friedman

Medical Centers

  • Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden

  • Henderson Hospital, McMaster University Clinic, Hamilton, ON, Canada

  • Department of Medicine, McMaster University, Hamilton, ON, Canada

  • Medical Division , Municipal Hospital Friedrichstadt, Dresden, Germany

  • Thrombosis Research Institute and University College London, London, United Kingdom

Locations

  • Canada

  • Germany

  • Sweden

  • United Kingdom

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Deep vein thrombosis

  • Pulmonary embolism

Biomarkers

  • Creatinine

Drug/Treatment

  • Pradax

  • Hydroxyzine

  • Evithrom

Outcome

  • N/A

Study Design

  • observational

  • randomized

  • double blind/blinded

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved